Detalhe da pesquisa
1.
Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: A distinct subtype of iMCD-not otherwise specified with different clinical features and better survival.
Br J Haematol
; 204(5): 1830-1837, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38356434
2.
Sirolimus is effective for refractory/relapsed idiopathic multicentric Castleman disease: A single-center, retrospective study.
Ann Hematol
; 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38691144
3.
A phase 2 prospective study of bortezomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed iMCD.
Blood
; 141(21): 2654-2657, 2023 05 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-36928290
4.
Unicentric Castleman's disease presenting as amyloid A cardiac amyloidosis: a case report.
Ann Hematol
; 103(1): 367-368, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37882865
5.
Diagnostic Utility of Interferon-Gamma Release Assay in Tuberculous Lymphadenitis.
Chin Med Sci J
; 34(4): 233-240, 2019 Nov 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33906708
6.
A prospective study of zanubrutinib, a Bruton tyrosine kinase inhibitor, in relapsed/refractory idiopathic multicentric Castleman disease.
Int J Hematol
; 119(6): 631-637, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38546960
7.
A prospective, multicenter study of bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory iMCD.
Leuk Lymphoma
; 63(3): 618-626, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35100929
8.
UCD with MCD-like inflammatory state: surgical excision is highly effective.
Blood Adv
; 5(1): 122-128, 2021 01 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33570636